“The Weldon School of Biomedical Engineering is pleased to welcome Drs. Lee, Sahlein, and Wilson as adjunct assistant professors,” said Nan Kong, interim head and professor of the Weldon School of Biomedical Engineering. “Biomedical Engineering is truly an interdisciplinary field merging engineering, medicine and the sciences to solve challenging healthcare problems. We look forward to a mutually rewarding engineering--medicine collaboration in improving millions of lives today and tomorrow. Every small step in biomedical engineering leads to a giant leap in the world of healthcare.”

Young L. Kim, a professor of the Weldon School of Biomedical Engineering has been granted two patents on his intellectual property, “Light-activated photoreaction via genetic hybridization of far-red fluorescent protein and silk.”

3MT is a fast-paced competition that challenges Purdue Graduate students to share their research in only three minutes. The audience chooses their favorite 3MT presentation of the 10. Cash awards are given.

Lee has invented a new glaucoma drainage device that combats the problem of biofouling. Using new advancements in technology, the device is "Smart" and can clear itself of harmful bio-buildup.

Twenty-four students from the Weldon School of Biomedical Engineering and the College of Engineering spent the week in Ireland visiting medical device and pharma manufacturers in Castlebar, Galway, Limerick and Cork.

Election to AIMBE’s College of Fellows is limited to the top 2% of medical and biological engineers in these fields. Those elected are considered to have made outstanding contributions to engineering and medicine research, practice or education.

The Bioengineering Machine Learning Lab team, led by Young Kim, took a trip to Eldoret, Kenya to get a first-hand look at how their lab could directly impact global health—saving thousands of mothers and babies.

Purdue researcher leads teams creating patent-pending smart contacts for glaucoma, neovascularization, and dry eyes

The early bird gets the worm, and early detection can catch disease sooner, when treatment can be more effective. That’s as true for the first onset of a disease as for a relapse. Disease doesn’t always occur only once — even after cure, there can be a reversion. Just as early detection is critical to treating the original occurrence, it’s vital to catch the warning signs — the biomarkers — of the relapse in time to initiate a new round of therapeutic intervention.